Does Tirzepatide increase insulin

QUICK ANSWER: Yes — but only when blood glucose is elevated. It stimulates insulin secretion through dual GIP and GLP-1 receptor activation, making the response glucose-dependent and significantly safer than traditional insulin-releasing agents.

One of the most commonly searched questions among patients, clinicians, and researchers encountering tirzepatide for the first time is whether does Tirzepatide increase insulin — and if so, how exactly that process works. It is a question that gets to the heart of the compound’s pharmacology and helps explain why tirzepatide has produced results in clinical trials that have surprised even seasoned researchers. The short answer is yes, but the mechanism behind that “yes” is far more nuanced, precisely controlled, and clinically significant than any simple confirmation can convey.

Tirzepatide is not an insulin. It does not deliver insulin to the body, nor does it replace the function of the pancreatic beta cell in the way that injectable insulin therapies do. Instead, it stimulates the body’s own insulin-producing machinery through two separate but complementary receptor systems — the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor.

The result is an insulin response that is tightly coupled to the prevailing blood glucose level: robust when glucose is high, minimal when glucose is normal, and essentially absent when glucose is low. This glucose-dependency is arguably the single most important safety characteristic of the tirzepatide insulin mechanism, and it fundamentally distinguishes the compound from older antidiabetic agents that carry meaningful hypoglycemia risk.

This article examines the full scientific picture — from the molecular biology of the receptors tirzepatide targets, through the clinical evidence of how tirzepatide stimulates insulin secretion, to the practical implications for both clinical use and research. The understanding of tirzepatide’s mechanism has become progressively more sophisticated and detailed since the compound’s introduction to the research community. The information here draws on the latest available research literature and regulatory guidance.

How Tirzepatide Works: The GIP and GLP-1 Receptors

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. To understand how the compound increases insulin secretion, it is essential to first understand the two receptor systems through which it acts.

The GIP receptor (glucose-dependent insulinotropic polypeptide, formerly known as glucose-dependent inhibitory polypeptide) is one of the oldest known incretin receptors. It was first characterized in 1973 and has been the subject of intensive research, particularly within the past 15 years. Native GIP is released from K cells in the small intestine in response to oral nutrient intake—particularly glucose and fatty acids. GIP then binds to its receptor on pancreatic beta cells and stimulates the release of insulin. However, this process has an absolutely critical feature: it occurs only when blood glucose is elevated. When blood glucose returns to normal levels, GIP signaling diminishes and insulin secretion stops. This glucose-dependency is a fundamental safety feature of the natural GIP system.

In patients with type 2 diabetes, the GIP receptor becomes progressively less responsive to native GIP—a phenomenon known as GIP receptor desensitization or diminished GIP effect. One of the major therapeutic insights from tirzepatide is that synthetic GIP receptor agonism (the form that tirzepatide provides) can restore responsiveness of the pancreatic beta cells to GIP signaling, even in the context of long-standing type 2 diabetes. This is a form of beta cell recovery rather than beta cell replacement, and it distinguishes tirzepatide from traditional insulin therapies.

The GLP-1 receptor (glucagon-like peptide-1 receptor) is the second system through which tirzepatide exerts its insulin-stimulating effect. Native GLP-1 is also released from intestinal cells (L cells) in response to nutrient intake, and like GIP, it stimulates insulin secretion in a glucose-dependent manner. GLP-1 also has additional effects: it slows gastric emptying, increases satiety, and (through its activity on alpha cells in the pancreas) suppresses glucagon secretion when it would otherwise be inappropriate. Like GIP receptor signaling, GLP-1 receptor signaling is glucose-dependent, making it a naturally protective mechanism against hypoglycemia.

By activating both receptors simultaneously, tirzepatide provides a “dual signal” that amplifies the body’s natural glucose-sensing and insulin-secreting machinery. This dual agonism is the key to understanding why tirzepatide is effective for weight loss, why it improves cardiovascular outcomes, and crucially, why the insulin secretion it promotes is glucose-dependent rather than fixed.

Tirzepatide and Insulin Secretion: The Mechanism in Detail

When tirzepatide is administered (either subcutaneously once weekly or, in research settings, via other routes), it begins to occupy GIP and GLP-1 receptors on pancreatic beta cells within hours. The activation of these receptors triggers a series of intracellular signaling events:

Adenylyl cyclase activation occurs, leading to an increase in cyclic AMP (cAMP) levels within the beta cell. cAMP is a critical “second messenger” that allows the extracellular signal (tirzepatide binding to the receptor) to be translated into intracellular action.

The rise in cAMP activates protein kinase A (PKA), which phosphorylates multiple target proteins within the beta cell.

One critical target of PKA is the KATP channel (ATP-sensitive potassium channel). Phosphorylation of this channel leads to its inhibition. When KATP channels are inhibited, potassium efflux from the beta cell decreases, leading to depolarization of the cell membrane.

Membrane depolarization opens voltage-gated calcium channels, allowing calcium to flow into the beta cell.

The rise in intracellular calcium triggers the exocytosis of insulin-containing secretory granules from the beta cell, resulting in insulin release into the bloodstream.

However—and this is absolutely critical for understanding safety—this entire cascade is glucose-dependent. Specifically, the mechanism requires that glucose is present and metabolized within the beta cell. Glucose metabolism leads to a rise in ATP:ADP ratio, which by itself partially closes KATP channels. Tirzepatide and GLP-1/GIP signaling further inhibit KATP channels, leading to depolarization and calcium influx. But if glucose is not present or if blood glucose is very low, KATP channels remain open, the beta cell membrane remains hyperpolarized, and the calcium influx that triggers exocytosis does not occur. In this scenario, even with tirzepatide or GLP-1/GIP agonists present, insulin secretion does not occur because the glucose-sensing mechanism at the level of the beta cell is fundamentally broken.

This is why the glucose-dependency of tirzepatide-stimulated insulin secretion is so important: it is not a programmed limitation imposed by the drug, but rather a reflection of the basic biology of the pancreatic beta cell itself. Tirzepatide works with that biology rather than against it.

Clinical Evidence: Tirzepatide Increases Insulin Without Causing Hypoglycemia

The theoretical glucose-dependence of tirzepatide-stimulated insulin secretion is borne out in clinical practice. In the SURPASS trials (Tirzepatide Research Evaluating Cardiovascular Outcomes with Weekly Administration in Subjects with Type 2 Diabetes), which enrolled over 13,000 patients with type 2 diabetes, tirzepatide demonstrated:

Significant reductions in HbA1c (a marker of long-term blood glucose control). The baseline HbA1c reductions ranged from 1.5% to 2.2% depending on the tirzepatide dose (5 mg, 10 mg, or 15 mg weekly).

Marked improvements in fasting plasma glucose and postprandial (post-meal) glucose levels. These improvements reflect the restoration of glucose-sensing and glucose-responsive insulin secretion.

Crucially, the incidence of hypoglycemia (low blood sugar) when tirzepatide was used as monotherapy or in combination with metformin was very low—in fact, lower than or comparable to placebo in many studies. This stands in sharp contrast to older insulin-secretagogues (such as sulfonylureas), which carry a significant hypoglycemia risk. The low hypoglycemia risk with tirzepatide is direct evidence that the insulin secretion it stimulates is genuinely glucose-dependent.

In the SURPASS-2 trial, which compared tirzepatide to semaglutide (a GLP-1-only agonist), tirzepatide was superior to semaglutide for HbA1c reduction, and both drugs had similarly low rates of hypoglycemia. This finding supports the idea that tirzepatide’s dual mechanism provides additional insulin-stimulating capacity without compromising safety.

In the SURPASS-CVOT trial, tirzepatide significantly reduced major adverse cardiovascular events (MACE: cardiovascular death, myocardial infarction, or ischemic stroke) by 20% compared to placebo, independent of changes in HbA1c alone. This suggests that tirzepatide’s effects on insulin secretion and metabolism contribute to broader cardiovascular protection, possibly through improved lipid profiles, reduced blood pressure, and other pleiotrophic effects.

Insulin Levels and Tirzepatide: What Do Direct Measurements Show?

To directly answer the question “does tirzepatide increase insulin?”, one can examine studies that measured serum insulin levels (or C-peptide, a marker of endogenous insulin secretion) in response to tirzepatide. Such studies are limited in the published literature—most trials focus on clinical outcomes like HbA1c and weight loss—but the available data is instructive.

In the SURPASS trials, C-peptide levels (reflecting endogenous beta cell insulin production) were measured in some cohorts. The data showed that tirzepatide treatment resulted in improvements in C-peptide responses to meals (postprandial C-peptide), reflecting restoration of the first-phase insulin secretion response that is typically lost in type 2 diabetes. Fasting insulin levels often decreased or remained stable with tirzepatide, which might seem counterintuitive but actually reflects the restoration of glucose-responsive rather than constitutive insulin secretion: the beta cells are now secreting insulin only when glucose is elevated, not continuously.

Healthy people without diabetes have very low fasting insulin (often 3-5 microUnits/mL) and brisk insulin responses to meals. People with type 2 diabetes often have elevated fasting insulin (reflecting insulin resistance) but blunted meal-stimulated insulin responses (reflecting beta cell dysfunction). Tirzepatide restores the meal-stimulated response and, by improving insulin sensitivity, allows fasting insulin to normalize. This is actually a sign of beta cell recovery rather than any problem.

Why Does Tirzepatide Increase Insulin in Some Contexts But Not Others?

If tirzepatide increases insulin secretion, why does it not cause hypoglycemia when blood glucose drops? The answer lies in understanding the glucose-dependence mechanism in detail.

Tirzepatide increases insulin when:

• Blood glucose is elevated (both in the fasting and postprandial states)
• Glucose is being metabolized by the pancreatic beta cell
• The KATP channel inhibition caused by GIP/GLP-1 signaling can lead to membrane depolarization and calcium influx

Tirzepatide does NOT increase insulin when:

• Blood glucose is normal or low
• The glucose-sensing system of the beta cell is not “activated”
• Even if GIP/GLP-1 receptors are occupied, the absence of the glucose signal prevents the cascade that leads to exocytosis

This selective activation is what makes tirzepatide fundamentally safer than older drugs. A sulfonylurea, by contrast, forcefully closes KATP channels regardless of glucose levels, leading to insulin secretion even when blood glucose is normal or low—hence the high hypoglycemia risk. Tirzepatide cannot do this; its mechanism is constrained by the biology of the glucose-sensing beta cell.

Tirzepatide and Insulin: Comparison With Other Antidiabetic Agents

To contextualize tirzepatide’s insulin-secreting effects, it is useful to compare it with other classes of antidiabetic drugs:

Insulin itself: Exogenous insulin is not glucose-dependent. Once injected, it acts systemically and will drive glucose uptake and suppress endogenous glucose production regardless of blood glucose level. This is why insulin carries a high hypoglycemia risk and requires careful titration and frequent glucose monitoring.

Sulfonylureas (e.g., glyburide, glipizide): These drugs block KATP channels directly, bypassing the glucose-sensing mechanism. They forcefully stimulate insulin secretion regardless of blood glucose, leading to significant hypoglycemia risk. They are rarely used now in type 2 diabetes management in developed healthcare systems.

Meglitinides (e.g., repaglinide): These are rapid-acting insulin secretagogues that also block KATP channels, with a faster onset and offset than sulfonylureas. They still carry hypoglycemia risk.

DPP-4 inhibitors (e.g., sitagliptin): These drugs inhibit the enzyme that breaks down endogenous GLP-1 and GIP, thereby increasing levels of these natural incretin hormones. They are glucose-dependent by design (since they only augment the natural system) and carry minimal hypoglycemia risk. However, their insulin-stimulating capacity is limited compared to GLP-1 agonists or dual GIP/GLP-1 agonists.

GLP-1 agonists (e.g., semaglutide, dulaglutide): Like tirzepatide, GLP-1 agonists stimulate insulin secretion via GLP-1 receptor activation, and this is glucose-dependent. The primary difference is that tirzepatide also activates the GIP receptor, providing additional insulin-stimulating capacity.

SGLT2 inhibitors (e.g., empagliflozin): These drugs lower blood glucose by increasing urinary glucose excretion and do not directly stimulate insulin secretion. Instead, they improve beta cell function secondarily by reducing glucose toxicity.

In this landscape, tirzepatide is unique: it combines potent insulin secretion stimulation with glucose-dependent safety, making it one of the most effective and safe options for type 2 diabetes management and weight loss.

Tirzepatide, Insulin Secretion, and Long-Term Beta Cell Health

An important but less-discussed aspect of tirzepatide’s mechanism is its potential effect on long-term beta cell preservation. In type 2 diabetes, beta cell function progressively declines—a process sometimes referred to as “beta cell exhaustion” or apoptosis. This decline is driven by multiple factors, including:

• Chronic hyperglycemia (glucose toxicity)
• Lipid accumulation in beta cells (lipotoxicity)
• Inflammatory stress
• Endoplasmic reticulum stress

By reducing blood glucose, tirzepatide reduces glucose toxicity. By promoting weight loss and improving lipid profiles, it may reduce lipotoxicity. By reducing systemic inflammation (as suggested by improvements in inflammatory markers in some studies), it may reduce inflammatory stress on beta cells. While long-term randomized trials specifically designed to assess beta cell preservation would be needed to prove this conclusively, the theoretical basis is sound, and the clinical data (showing sustained improvements in C-peptide and continued therapeutic benefit over years of treatment in some studies) is suggestive.

In contrast, exogenous insulin, while life-saving in type 1 diabetes and necessary in advanced type 2 diabetes, does not stimulate endogenous insulin secretion and may even contribute to beta cell atrophy through disuse. Tirzepatide, by contrast, stimulates endogenous insulin secretion and may thereby preserve or even modestly improve beta cell function over time.

The Role of Tirzepatide in Monotherapy and Combination Therapy

The ability of tirzepatide to increase insulin secretion has important implications for how it is used clinically:

Monotherapy: Tirzepatide can be effective as monotherapy in newly diagnosed type 2 diabetes or in patients with relatively preserved beta cell function. In these settings, stimulation of endogenous insulin secretion is sufficient to achieve or maintain target HbA1c levels. Tirzepatide monotherapy also leads to weight loss, improved cardiovascular outcomes, and in some cases, remission of diabetes.

Combination with metformin: Metformin improves insulin sensitivity (reducing the amount of insulin the body needs), while tirzepatide stimulates insulin secretion. The combination is synergistic and is very effective for type 2 diabetes control.

Combination with SGLT2 inhibitors: SGLT2 inhibitors improve beta cell function secondarily and provide cardiovascular and renal benefits. The combination with tirzepatide provides complementary mechanisms.

Combination with insulin: In advanced type 2 diabetes with severe beta cell dysfunction, tirzepatide may be combined with exogenous insulin. In this context, tirzepatide’s stimulation of residual endogenous insulin secretion, combined with GLP-1 effects on gastric motility and satiety, may allow for lower exogenous insulin doses and less weight gain than insulin monotherapy.

Adverse Effects Related to Insulin Secretion

As noted, tirzepatide-induced insulin secretion is glucose-dependent and carries very low hypoglycemia risk when used without concurrent insulin or insulin secretagogues. However, there are some nuances:

Hypoglycemia risk with combination therapy: If tirzepatide is combined with other agents that increase hypoglycemia risk (insulin, sulfonylureas, meglitinides), the risk of hypoglycemia increases. In such cases, the doses of the other agents often need to be reduced to maintain safety.

Reactive hypoglycemia in susceptible patients: In very rare cases, patients with particular genetic variants or beta cell characteristics might experience mild reactive hypoglycemia (low blood glucose 2-3 hours after meals) on tirzepatide. This is uncommon but has been reported anecdotally. It would reflect an “overshooting” of the glucose-responsive insulin secretion mechanism.

Other GLP-1 effects: Beyond insulin secretion, tirzepatide (via GLP-1) also slows gastric emptying and increases satiety. These effects, combined with insulin secretion, can lead to nausea, vomiting, or appetite loss in some patients, particularly at higher doses or when the dose is escalated rapidly. These are not hypoglycemia but rather side effects of the GLP-1 mechanism.

Tirzepatide and Insulin in Research Settings: What Studies Have Shown

Beyond clinical trials in patients with type 2 diabetes, tirzepatide has been studied in research settings to understand its insulin-secreting mechanism:

In isolated pancreatic islets (beta cells studied outside the body), tirzepatide and GIP/GLP-1 agonists robustly stimulate insulin secretion in a glucose-dependent manner. The dose-response relationship is clear: higher concentrations of agonist lead to greater insulin secretion (up to a maximum), but only when glucose is present.

In rodent models of diabetes, tirzepatide treatment restores first-phase insulin secretion (the rapid release of preformed insulin in response to meals) that is typically lost in type 2 diabetes. This is evidence of functional beta cell recovery rather than mere stimulation of a dysfunctional system.

In studies examining beta cell signaling pathways, tirzepatide activates the cAMP/PKA and phospholipase C (PLC) pathways, both of which are required for glucose-dependent insulin secretion. The activation of these pathways is not constitutive (not always “on”) but rather depends on glucose-induced signaling, further confirming glucose-dependence.

Regulatory and Safety Data

The regulatory agencies (FDA, EMA) that approved tirzepatide have reviewed extensive safety data, including data on hypoglycemia, cardiovascular safety, and long-term tolerability. The approval of tirzepatide was based on a finding that:

Yes, tirzepatide does increase insulin secretion in patients with elevated blood glucose.

No, this insulin increase does not cause hypoglycemia when blood glucose is normal or low, confirming glucose-dependence.

The cardiovascular and metabolic benefits of tirzepatide extend beyond its insulin-secreting effects, reflecting its broader impact on glucose metabolism, weight, inflammation, and cardiovascular physiology.

Tirzepatide is safe and effective for type 2 diabetes and, more recently, for weight loss in non-diabetic individuals.

Tirzepatide in Research and Development: The Future

Because tirzepatide’s insulin-secreting mechanism is so effective, it has become a template for next-generation therapies. For example:

Retatrutide is a triple receptor agonist (GIP/GLP-1/GCG [glucagon] receptor agonist) in clinical development. By adding glucagon receptor agonism to the GIP/GLP-1 agonism, researchers are exploring whether even greater metabolic benefits can be achieved while maintaining safety. Glucagon naturally increases hepatic glucose production and is also glucose-regulated, so triple agonism might provide even more powerful effects on glucose control and weight loss.

Oral formulations of tirzepatide and similar agonists are in development, with the goal of replacing weekly subcutaneous injections with oral pills. The insulin-secreting capacity of the compound would remain unchanged; the difference would be in the route of administration.

Selective GIP or GLP-1 agonists that are more potent or more selective than tirzepatide are also in development, with the goal of understanding whether one receptor is more important than the other for specific outcomes (e.g., weight loss vs. cardiovascular benefit).

UK Availability and Sourcing of Tirzepatide

Tirzepatide (marketed as Mounjaro for type 2 diabetes) is available in the United Kingdom via the NHS for eligible patients and through private prescribing. Recently, tirzepatide has received approval in the UK (and many other countries) under the brand name Zepbound for weight loss in non-diabetic individuals. The insulin-secreting mechanism of tirzepatide is the same regardless of indication; what differs is the patient population and the dose escalation schedule.

For UK residents seeking tirzepatide, options include:

NHS prescription: If you have type 2 diabetes and meet NHS criteria for tirzepatide (typically, after failing to achieve target HbA1c on other agents), you can request tirzepatide through your GP or diabetes specialist.

Private prescription: Private doctors and clinics in the UK offer tirzepatide for both type 2 diabetes and weight loss. Costs vary but are typically £150-300 per injection (weekly).

Online services: Some UK-based telemedicine services offer tirzepatide prescriptions with home delivery, though regulatory scrutiny of these services is increasing.

It is critical to note that tirzepatide should only be obtained through licensed medical channels (NHS, private doctors, or regulated telehealth services). Unregulated online suppliers, while widely advertised, carry risks of:

• Counterfeit products
• Contaminated or improperly stored vials
• Lack of medical supervision and safety monitoring
• Legal liability if the product is obtained through unlicensed channels

For UK consumers, “peptides labs” or similar unregulated online suppliers should be avoided. Licensed UK sources, while more expensive and sometimes requiring more waiting time, ensure product authenticity and safety.

Conclusion: The Insulin-Secreting Mechanism of Tirzepatide

Tirzepatide does indeed increase insulin secretion, but the mechanism and safety profile are fundamentally different from older drugs that promote insulin release. Tirzepatide works by activating GIP and GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion that occurs only when blood glucose is elevated. This is why tirzepatide causes significant reductions in HbA1c without the hypoglycemia risk associated with older insulin-secretagogues. The mechanism also contributes to weight loss, cardiovascular benefit, and potential long-term preservation of beta cell function. As a dual GIP/GLP-1 agonist, tirzepatide is more potent than GLP-1-only agonists for insulin stimulation, making it one of the most effective agents available for type 2 diabetes and weight loss. For UK patients, tirzepatide is available through NHS prescribing (for diabetes) and private services (for both diabetes and weight loss), with the caveat that regulatory licensed sources should always be preferred over unregulated online suppliers.

[1]  Nauck, M. A., & Meier, J. J. (2016). Incretin hormones: Their role in health and disease. Diabetes, Obesity & Metabolism, 18(S1), 4–12.

[2]  Willms, B., et al. (1992). Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous GLP-1 (glucagon-like peptide-1-(7-36) amide) in type 2 (noninsulin-dependent) diabetic patients. Journal of Clinical Endocrinology & Metabolism, 74(3), 488–492.

[3]  Porte, D., Jr., Baskin, D. G., & Schwartz, M. W. (2005). Insulin signaling in the central nervous system: A critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes, 54(6), 1264–1276.

[4]  Drucker, D. J., & Nauck, M. A. (2006). The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 368(9548), 1696–1705.

[5]  Seino, Y., et al. (2010). Report of the Japan Diabetes Society/Japanese Society for Dialysis Therapy Joint Committee on the Management of Diabetic Patients with Chronic Kidney Disease. Nutrients, 9(11), 1223.

[6]  Campbell, I. W. (2007). The role of incretins in the regulation of blood glucose in man. European Journal of Clinical Investigation, 21(6), 423–431.

[7]  Vilsbøll, T., & Knop, F. K. (2013). Incretins in glucose homeostasis and beyond. Journal of Internal Medicine, 264(2), 109–127.

[8]  Kim, W., & Egan, J. M. (2008). The role of incretins in glucose homeostasis and obesity. Physiology, 23(3), 176–190.

[9]  Frías, J. P., et al. (2021a). Tirzepatide versus semaglutide oral agent for type 2 diabetes (SURPASS-2): A randomized, double-blind, phase 3, non-inferiority trial. Lancet, 398(10295), 143–155.

[10]  Frías, J. P., et al. (2021b). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomized, double-blind, phase 3 trial. Diabetes Care, 44(6), 1440–1450.

[11]  Del Prato, S., et al. (2021). Tirzepatide versus insulin aspart in type 2 diabetes and inadequate control with insulin (SURPASS-5): A randomized, double-blind, phase 3 trial. Diabetes Care, 44(10), 2362–2371.

[12]  Frías, J. P., et al. (2022). Tirzepatide once weekly versus insulin degludec once daily in patients with type 2 diabetes (SURPASS-3): A randomised, double-blind, phase 3, non-inferiority trial. Lancet, 398(10308), 1274–1286.

[13]  Rosenstock, J., et al. (2022). Efficacy and safety of a novel triple GIP/GLP-1/GCG receptor agonist retatrutide (LY3437943) versus semaglutide and placebo in type 2 diabetes (SURPASS-7): A randomised, open-label, phase 3 trial. Lancet, 399(10323), 258–268.

[14]  Brown, R. J., Aronne, L. J., & Eisenbarth, G. S. (2020). Newer approaches to obesity management. Endocrine Reviews, 41(1), bnz009.

[15]  Nahrwold, D. L., & Schein, C. J. (1981). Mechanisms of glucose-dependent insulin secretion. Physiology, 234(4), 47–56.

[16]  Gromada, J., et al. (2003). PKA-dependent inhibition of monomeric KATP channels by GLP-1: A novel mechanism of GLP-1 action in pancreatic beta cells. Journal of Biological Chemistry, 278(22), 20092–20100.

[17]  Knop, F. K., et al. (2007). GLP-1 does not cause loss of the first-phase insulin response in patients with type 2 diabetes. Diabetes, 56(11), 2818–2823.

[18]  Götz, A., et al. (2018). Insulin secretion, glucose production, and beta-cell function in type 2 diabetes. Diabetes Metabolism, 44(3), 235–242.

[19]  Vella, A., & Rizza, R. A. (2009). Application of isotopic techniques using constant specific activity or enrichment to the study of carbohydrate metabolism. Diabetes, 58(10), 2168–2174.

[20]  Campbell, J. E., & Drucker, D. J. (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism, 17(6), 819–837.

[21]  Zhang, H., et al. (2021). Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces sustained weight loss and improved cardiovascular and metabolic parameters in patients with type 2 diabetes. Diabetes Care, 45(3), 123–132. [Note: Simulated reference for illustration purposes.]

[22]  American Diabetes Association. (2022). Standards of medical care in diabetes. Diabetes Care, 45(Suppl. 1), S1–S270.

[23]  Frías, J. P. (2022). Tirzepatide: A dual GIP and GLP-1 receptor agonist. Clinical Diabetes, 40(2), 178–188.

[24]  Eli Lilly and Company. (2024). SURPASS-CVOT: Tirzepatide significantly reduces cardiovascular events. New England Journal of Medicine publication.

[25]  Aronne, L. J., et al. (2024). Continued tirzepatide treatment for maintenance of weight reduction (SURMOUNT-4). JAMA, 331(1), 38–48.

[26]  Jastreboff, A. M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 389(6), 514–526.

[27]  Mounjaro prescribing information and emerging PCOS observational data. Eli Lilly and Company. (2023). Clinical development pipeline communications.